Floatz logo

PEGYINTERFERON-ALFA-2A

Chronic Hepatitis B Virus Infection

Huashan Hospitalprotein_peptidePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Chronic Hepatitis B Virus Infection cohort.

Asset / SponsorPhaseRating
Lamivudine
Yonsei University
Phase 4BBB
Entecavir
Beijing Continent Pharmaceutical Co, Ltd.
Phase 4BBB
Telbivudine
The Fifth People's Hospital of Suzhou
Phase 4BBB
Tenofovir Disoproxil Fumarate
Ningbo No.2 Hospital
Phase 4BBB
Adefovir Dipivoxil
Asian-Pacific Alliance of Liver Disease, Beijing
Phase 4BB

View all 25 →

Same molecule, other indications

PEGYINTERFERON-ALFA-2A is also rated in:

hepatitis C virus infectionDormant
A
Indicative · Phase 4
81 / 100
View asset →
chronic hepatitis C virus infectionDormant
A
Indicative · Phase 4
81 / 100
View asset →
HIV infectious diseaseDormant
BB
Indicative · Phase 3
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →